Abstract
Qin S, Chan SL, Sukeepaisarnjaroen W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2019; 11: 1-12. DOI: 10.1177/1758835919889001
In this article, the following errors were made while processing the article:
On page 1, the correct affiliation of the author Hongming Pan is “Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China”
On page 3, heading Results, sub-heading Patient demographics and disposition, line 11, the correct sentence reads as: “All patients were Asian, the majority with moderately to poorly differentiated HCC, with a mean age of 55.6 years, 89% were men, 53% had an ECOG performance status of 0, and distant metastases were present in 39% of patients (Table 1).”
On page 4, heading Results, sub-heading Safety, line 2, the correct sentence reads as: “The most common (>30%) AEs, regardless of causality, were nausea (42%), vomiting (37%), diarrhea (34%), aspartate transaminase (AST) increased, and decreased appetite (both 32%, Table 2).”
The online version of the paper has been corrected.